Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab +/- Lenalidomide vs Lenalidomide in Newly Diagnosed Multiple Myeloma Maintenance
NCT05243797Phase 3Recruiting
- Start
- Sep 2022
- Primary completion
- Apr 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of teclistamab in multiple myeloma (MM). Started Sep 2022; status: recruiting.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05243797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05243797.